Communication with shareholders, investors and analysts is a
priority for Pronova BioPharma ASA.
The company’s objective is to ensure that the financial market
and the shareholders have sufficient information about Pronova
BioPharma to be certain that pricing reflects underlying values.
Care will be taken by Pronova BioPharma to ensure an impartial
distribution of information when dealing with shareholders and
analysts.
The company will arrange open investor presentations
in connection with its annual and quarterly reports. Presentations
made for investors in connection with the annual and quarterly reports
will be made available on the Pronova BioPharma website. Important
events affecting Pronova BioPharma will be reported immediately.
Pronova BioPharma shall present its provisional annual accounts
in February each year. Complete annual accounts and the annual
report will be sent to all shareholders in April each year.
Pronova BioPharma will present its accounts on a quarterly basis, no
later than 45 days after each quarter has ended.
All information will be given in English. Information required to be
given in Norwegian will also be given in English.
Head of investor relation and chief financial officer will be responsible
for communication with shareholders outside the general meeting.
